The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
Meningitis, Cryptococcal, HIV Infections
About this trial
This is an interventional treatment trial for Meningitis, Cryptococcal focused on measuring AIDS-Related Opportunistic Infections, Meningitis, Drug Therapy, Combination, Antifungal Agents, Acquired Immunodeficiency Syndrome, Amphotericin B
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Up to 1 mg/kg amphotericin B for the current episode of cryptococcal meningitis. Patients must have: HIV infection. Acute cryptococcal meningitis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Cardiovascular disorders including congestive heart failure, uncontrolled hypertension (seated diastolic blood pressure > 95 mm Hg), or symptomatic ischemic heart disease (angina). Orthostatic hypotension, defined as a decrease in systolic blood pressure of >= 20 mm Hg upon standing. Coma. Other CNS disease (e.g., other intracranial infections) that may interfere with assessment of response. Opening CSF pressure >= 350 mm or papilledema. (For patients with recurrent disease, evidence of mass effect on either MRI or CT excludes.) Any concurrent disease that would preclude participation in the study. Patients with the following prior conditions are excluded: History of any bleeding disorder. History of active renal or hepatic disease. Myocardial infarction within the previous 3 months. Stroke within the previous 3 months.
Sites / Locations
- Los Angeles County - USC Med Ctr
- UCI Med Ctr
- UCSD Treatment Ctr
- Univ of Kansas School of Medicine
- SUNY / Health Sciences Ctr at Stony Brook
- Duke Univ Med Ctr
- East Carolina Univ School of Medicine
- Bowman Gray School of Medicine
- Case Western Reserve Univ
- Pennsylvania State Univ / Hershey Med Ctr
- Univ TX Galveston Med Branch